CAI logo

CAI
Caris Life Sciences Inc.

885
Mkt Cap
$5.1B
Volume
2.72M
52W High
$42.50
52W Low
$16.28
PE Ratio
-9.42
CAI Fundamentals
Price
$18.05
Prev Close
$19.20
Open
$19.25
50D MA
$19.72
Beta
0.72
Avg. Volume
2.73M
EPS (Annual)
-$1.90
P/B
8.83
Rev/Employee
$439,887.87
$7,250.15
Loading...
Loading...
News
all
press releases
Caris Life Sciences (NASDAQ:CAI) Stock Price Down 6.9% - What's Next?
Caris Life Sciences (NASDAQ:CAI) Stock Price Down 6.9% - Here's What Happened...
MarketBeat·22h ago
News Placeholder
More News
News Placeholder
Caris Life Sciences (NASDAQ:CAI) Now Covered by Piper Sandler
Piper Sandler started coverage on Caris Life Sciences in a report on Friday. They set a "neutral" rating and a $21.00 price target on the stock...
MarketBeat·1d ago
News Placeholder
Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients
Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients Caris Life Sciences Introduces Multimodal...
PR Newswire·3d ago
News Placeholder
58,725 Shares in Caris Life Sciences, Inc. $CAI Acquired by Hamilton Lane Advisors LLC
Hamilton Lane Advisors LLC bought a new stake in shares of Caris Life Sciences, Inc. (NASDAQ:CAI - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the...
MarketBeat·7d ago
News Placeholder
Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies
Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies Caris Life Sciences Announces Launch of...
PR Newswire·9d ago
News Placeholder
Caris Life Sciences, Inc. (NASDAQ:CAI) Receives Consensus Recommendation of "Hold" from Analysts
Caris Life Sciences, Inc. (NASDAQ:CAI - Get Free Report) has been given a consensus recommendation of "Hold" by the five analysts that are currently covering the company, Marketbeat reports. One...
MarketBeat·10d ago
News Placeholder
Why Is Caris Life Sciences Stock Gaining Wednesday?
Caris Life Sciences stock surges on positive Achieve 1 cancer test data. See key CAI levels and study results here.read more...
Benzinga·10d ago
News Placeholder
The Goldman Sachs Group Begins Coverage on Caris Life Sciences (NASDAQ:CAI)
The Goldman Sachs Group assumed coverage on Caris Life Sciences in a research note on Wednesday. They issued a "buy" rating and a $27.00 price target on the stock...
MarketBeat·10d ago
News Placeholder
Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect
Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the...
PR Newswire·11d ago
News Placeholder
Zevenbergen Capital Investments LLC Takes $14.66 Million Position in Caris Life Sciences, Inc. $CAI
Zevenbergen Capital Investments LLC purchased a new position in shares of Caris Life Sciences, Inc. (NASDAQ:CAI - Free Report) in the 4th quarter, according to its most recent 13F filing with the...
MarketBeat·11d ago
<
1
2
...
>

Latest CAI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.